Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lactitol

FDA-approved product (for solution, oral), marketed as Pizensy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lactitol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Constipation disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Osmotically acting laxatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lactitol, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lactitol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lactitol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients

    NCT06239376 · start 2024-02-19

    Registered record
    Registry ID
    NCT06239376
    Conditions
    Adenomyosis; IVF; Frozen Embryo Transfer
    Interventions
    GnRHa+AI - AC; Artificial cycle
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-02-19
    Completion
    2027-05-30
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis; IVF; Frozen Embryo Transfer
    InterventionGnRHa+AI - AC; Artificial cycle
    PhaseNot applicable
    Registry statusRecruiting

  • Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

    NCT05362799 · start 2022-06-01

    Registered record
    Registry ID
    NCT05362799
    Conditions
    Infertility, Female
    Interventions
    Letrozol (Femara, Novartis); Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt); highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland); highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-06-01
    Completion
    2023-12-31
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female
    InterventionLetrozol (Femara, Novartis); Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt); highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland); highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
    PhasePhase 4
    Registry statusUnknown

  • Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

    NCT05657158 · start 2021-08-23

    Registered record
    Registry ID
    NCT05657158
    Conditions
    Intraocular Inflammation; Retinal Vascular Occlusion
    Interventions
    Brolucizumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-23
    Completion
    2022-01-04
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Inflammation; Retinal Vascular Occlusion
    InterventionBrolucizumab
    PhaseNot recorded
    Registry statusCompleted

  • The Effect Of High And Low Molecular Weight Sodium Hyaluronic Acid Eye Drops After Crosslinking

    NCT06243991 · start 2021-03-01

    Registered record
    Registry ID
    NCT06243991
    Conditions
    Keratoconus
    Interventions
    in vivo Corneal Confocal Microscopy; Corneal Sensitivity; Non invasive tear break up time; Ocular Surface Disease Index Qestionnaire; Corneal tomography
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2023-02-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratoconus
    Interventionin vivo Corneal Confocal Microscopy; Corneal Sensitivity; Non invasive tear break up time; Ocular Surface Disease Index Qestionnaire +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Different Doses of vPDT in the Treatment of cCSC

    NCT05390619 · start 2020-01-01

    Registered record
    Registry ID
    NCT05390619
    Conditions
    Central Serous Chorioretinopathy; Therapy, Photodynamic
    Interventions
    50% dose of photodynamic therapy; 70% dose of photodynamic therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2023-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Serous Chorioretinopathy; Therapy, Photodynamic
    Intervention50% dose of photodynamic therapy; 70% dose of photodynamic therapy
    PhaseNot applicable
    Registry statusUnknown

  • Follicular Synchronization in PCOS Patients Undergoing ICSI

    NCT04069117 · start 2019-08-01

    Registered record
    Registry ID
    NCT04069117
    Conditions
    Polycystic Ovarian Syndrome
    Interventions
    letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-08-01
    Completion
    2022-02-20
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovarian Syndrome
    Interventionletrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

    NCT05192265 · start 2019-05-20

    Registered record
    Registry ID
    NCT05192265
    Conditions
    Malaria Fever; Plasmodium Falciparum Malaria; Uncomplicated Malaria
    Interventions
    Antimalarials, pyronaridine-artesunate; Antimalarials, Artemether + Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-05-20
    Completion
    2020-12-23
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Fever; Plasmodium Falciparum Malaria; Uncomplicated Malaria
    InterventionAntimalarials, pyronaridine-artesunate; Antimalarials, Artemether + Lumefantrine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

    NCT04619914 · start 2019-03-01

    Registered record
    Registry ID
    NCT04619914
    Conditions
    Endometrial Thickness; Pregnancy Rate
    Interventions
    Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt; letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-01
    Completion
    2019-08-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Thickness; Pregnancy Rate
    InterventionClomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt; letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer

    NCT03518528 · start 2018-08-30

    Registered record
    Registry ID
    NCT03518528
    Conditions
    Embryo Transfer; Infertility
    Interventions
    Estradiol 2 MG; Estradiol 100 µg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-08-30
    Completion
    2018-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmbryo Transfer; Infertility
    InterventionEstradiol 2 MG; Estradiol 100 µg
    PhaseNot recorded
    Registry statusUnknown

  • Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema

    NCT04089605 · start 2017-06-01

    Registered record
    Registry ID
    NCT04089605
    Conditions
    Diabetic Macular Edema
    Interventions
    dexamethasone implant; Ranibizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2019-04-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema
    Interventiondexamethasone implant; Ranibizumab
    PhasePhase 4
    Registry statusCompleted

  • SJ733 Induced Blood Stage Malaria Challenge Study

    NCT02867059 · start 2016-09-13

    Registered record
    Registry ID
    NCT02867059
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    (+)-SJ000557733
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-13
    Completion
    2016-12-22
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    Intervention(+)-SJ000557733
    PhasePhase 1
    Registry statusCompleted

  • Esomeprazole or Pantoprazole in Renal Transplantation

    NCT03812419 · start 2016-01-05

    Registered record
    Registry ID
    NCT03812419
    Conditions
    Kidney Transplant; Complications
    Interventions
    Esomeprazole 40 mg; Pantoprazole 40mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-01-05
    Completion
    2016-12-30
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant; Complications
    InterventionEsomeprazole 40 mg; Pantoprazole 40mg
    PhaseNot applicable
    Registry statusCompleted

  • To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

    NCT02596451 · start 2015-08

    Registered record
    Registry ID
    NCT02596451
    Conditions
    Osteoarthritis
    Interventions
    Diclofenac Sodium gel, 1%; Voltaren® Gel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08
    Completion
    2016-03
    Enrolment
    1,164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis
    InterventionDiclofenac Sodium gel, 1%; Voltaren® Gel; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

    NCT02251288 · start 2015-05-18

    Registered record
    Registry ID
    NCT02251288
    Conditions
    Avian Influenza; Immunisation
    Interventions
    Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca; Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; MF59 adjuvant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-05-18
    Completion
    2018-08-17
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAvian Influenza; Immunisation
    InterventionInfluenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca; Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; MF59 adjuvant
    PhasePhase 1
    Registry statusCompleted

  • Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

    NCT02343679 · start 2015-05

    Registered record
    Registry ID
    NCT02343679
    Conditions
    Hematologic Malignancies
    Interventions
    ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-05
    Completion
    2022-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancies
    Interventionceritinib
    PhasePhase 2
    Registry statusWithdrawn